bioAffinity Technologies Inc BIAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIAF is a good fit for your portfolio.
News
-
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
-
bioAffinity Technologies News Update
-
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
-
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
-
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
-
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
-
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
-
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
Trading Information
- Previous Close Price
- $1.87
- Day Range
- $1.80–1.94
- 52-Week Range
- $0.95–3.62
- Bid/Ask
- $1.65 / $2.21
- Market Cap
- $21.65 Mil
- Volume/Avg
- 88,285 / 248,711
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company’s product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- —
- Total Number of Employees
- 75
- Website
- https://www.bioaffinitytech.com
Valuation
|
Metric
|
BIAF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.62 |
Price/Sales | 6.46 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIAF
|
|---|---|
Quick Ratio | 1.62 |
Current Ratio | 1.77 |
Interest Coverage | −215.52 |
Quick Ratio
BIAF
Profitability
|
Metric
|
BIAF
|
|---|---|
Return on Assets (Normalized) | −73.56% |
Return on Equity (Normalized) | −90.33% |
Return on Invested Capital (Normalized) | −83.50% |
Return on Assets
BIAF
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Mykrvlbw | Fkh | $228.7 Bil | |
DHR
| Danaher Corp | Zplhlmvxm | Stsrhv | $195.1 Bil | |
A
| Agilent Technologies Inc | Rnyhckvs | Prtpc | $45.2 Bil | |
IQV
| IQVIA Holdings Inc | Szvdnccg | Csgscz | $42.1 Bil | |
IDXX
| IDEXX Laboratories Inc | Nchfqrjq | Qdprrkj | $41.5 Bil | |
MTD
| Mettler-Toledo International Inc | Wkhlxmnyh | Sspnsk | $32.5 Bil | |
ICLR
| Icon PLC | Dkmbzxnn | Mhwkyb | $26.6 Bil | |
WAT
| Waters Corp | Mslvmpmns | Qyzhx | $21.5 Bil | |
ILMN
| Illumina Inc | Xjktcgjd | Zczjlj | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Yzskwbcqqh | Ndcyk | $18.0 Bil |